Self-damage caused by dysregulation of the complement alternative pathway: Relevance of the factor H protein family

The alternative pathway is a continuously active surveillance arm of the complement system, and it can also enhance complement activation initiated by the classical and the lectin pathways. Various membrane-bound and plasma regulatory proteins control the activation of the potentially deleterious co...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez-Corral, Pilar, Pouw, Richard B., López Trascasa, Margarita, Józsi, Mihály
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/685193
Acceso en línea:http://hdl.handle.net/10486/685193
https://dx.doi.org/10.3389/fimmu.2018.01607
Access Level:acceso abierto
Palabra clave:Age-related macular degeneration
Atypical hemolytic uremic syndrome
C3 glomerulopathy
Complement activation
Complement de-regulation
Factor H
Factor H-related protein
Opsonization
Medicina
Descripción
Sumario:The alternative pathway is a continuously active surveillance arm of the complement system, and it can also enhance complement activation initiated by the classical and the lectin pathways. Various membrane-bound and plasma regulatory proteins control the activation of the potentially deleterious complement system. Among the regulators, the plasma glycoprotein factor H (FH) is the main inhibitor of the alternative pathway and its powerful amplification loop. FH belongs to a protein family that also includes FH-like protein 1 and five factor H-related (FHR-1 to FHR-5) proteins. Genetic variants and abnormal rearrangements involving the FH protein family have been linked to numerous systemic and organ-specific diseases, including age-related macular degeneration, and the renal pathologies atypical hemolytic uremic syndrome, C3 glomerulopathies, and IgA nephropathy. This review covers the known and recently emerged ligands and interactions of the human FH family proteins associated with disease and discuss the very recent experimental data that suggest FH-antagonistic and complement-activating functions for the FHR proteins